ERBB2-Mutated Metastatic Lung Adenocarcinoma With Treatment Intolerance and Progression
This lung cancer diagnosis at a glance
- Subtype
- Adenocarcinoma
- Biomarkers
- ERBB2 A775_G776 insYVMA mutation
- Sex
- male
- Treatment
- chemotherapy and targeted therapy
- Outcome
- Setback / Progression
Treatment course, step by step
- He received carboplatin and pemetrexed.
- Pemetrexed maintenance followed, with stable disease during 3.5 months of treatment, but tolerability was poor.
- Docetaxel plus ramucirumab was then given for 1 month and again produced stable disease with poor tolerability.
- Afatinib was then given for 1 month before symptomatic progression.
What happened, in summary
A man with metastatic lung adenocarcinoma had an ERBB2 A775_G776 insYVMA mutation and a limited smoking history. Carboplatin and pemetrexed followed by pemetrexed maintenance were given for 3.5 months. The disease remained stable, but he tolerated the treatment poorly. He then received docetaxel plus ramucirumab for 1 month. The cancer again remained stable, while treatment tolerance continued to be difficult. Afatinib was started next and continued for 1 month. His condition then worsened with symptomatic disease progression. His cancer had therefore progressed after several systemic and HER2-directed treatments, with treatment tolerability also shaping the earlier course.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Afatinib for Lung Cancer 37 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer